- Home
- DSGN vs NCZ Comparison
DSGN vs NCZ Comparison
Compare DSGN & NCZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- NCZ
- Stock Information
- Founded
- DSGN 2017
- NCZ 2003
- Country
- DSGN United States
- NCZ United States
- Employees
- DSGN N/A
- NCZ N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- NCZ Finance Companies
- Sector
- DSGN Health Care
- NCZ Finance
- Exchange
- DSGN Nasdaq
- NCZ Nasdaq
- Market Cap
- DSGN 208.9M
- NCZ 228.3M
- IPO Year
- DSGN 2021
- NCZ N/A
- Fundamental
- Price
- DSGN $7.14
- NCZ $13.67
- Analyst Decision
- DSGN
- NCZ
- Analyst Count
- DSGN 0
- NCZ 0
- Target Price
- DSGN N/A
- NCZ N/A
- AVG Volume (30 Days)
- DSGN 189.7K
- NCZ 533.0K
- Earning Date
- DSGN 11-06-2025
- NCZ 01-01-0001
- Dividend Yield
- DSGN N/A
- NCZ 12.16%
- EPS Growth
- DSGN N/A
- NCZ N/A
- EPS
- DSGN N/A
- NCZ N/A
- Revenue
- DSGN N/A
- NCZ N/A
- Revenue This Year
- DSGN N/A
- NCZ N/A
- Revenue Next Year
- DSGN N/A
- NCZ N/A
- P/E Ratio
- DSGN N/A
- NCZ N/A
- Revenue Growth
- DSGN N/A
- NCZ N/A
- 52 Week Low
- DSGN $2.60
- NCZ $2.50
- 52 Week High
- DSGN $7.77
- NCZ $3.15
- Technical
- Relative Strength Index (RSI)
- DSGN 65.47
- NCZ 48.49
- Support Level
- DSGN $5.98
- NCZ $13.54
- Resistance Level
- DSGN $6.61
- NCZ $13.72
- Average True Range (ATR)
- DSGN 0.38
- NCZ 0.17
- MACD
- DSGN 0.04
- NCZ -0.06
- Stochastic Oscillator
- DSGN 99.62
- NCZ 12.31
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.